

Special Issue

Synthesis of Bioactive Compounds

Message from the Guest Editor

In the past few decades, the emergence of new highly pathogenic strains of viruses and microorganisms such as SARS-CoV-2, drug-resistant tuberculosis and malaria (i.e., superbugs), has presented challenges that require urgent response. Effective treatment of cancer is another important and unresolved problem. Tumors develop through genetic and epigenetic changes that modify fundamental cellular programs for growth and proliferation, followed by the natural selection of reprogrammed cells that best adapt to the constant fight against human immunity and chemotherapy drugs. To address these issues, a number of breakthrough synthetic methodologies need to be developed which enable the efficient assembly of new molecules and make it possible to achieve the high variability of substituents necessary for studying structure–biological activity relationships. This Special Issue aims to gather scientific articles devoted to the synthesis and study of the activity of previously unknown compounds, as well as fully synthetic papers that describe new effective approaches to known biologically active compounds, without further evaluation of biological properties.

Guest Editor

Dr. Nicolai A. Aksenov

Department of analytic and organic chemistry, FSAEI HE "North-Caucasus Federal University", Stavropol, Russia

Deadline for manuscript submissions

closed (31 March 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/115366

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).